We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ranibizumab "Treat and Extend" in Diabetic Macular Edma (OPTIMAL)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01297569
First Posted: February 16, 2011
Last Update Posted: February 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
February 15, 2011
February 16, 2011
February 23, 2017
January 2011
November 2012   (Final data collection date for primary outcome measure)
Change in Best Corrected Visual Acuity(BCVA) [ Time Frame: from month 0 (baseline) to month 12 ]
Same as current
Complete list of historical versions of study NCT01297569 on ClinicalTrials.gov Archive Site
  • change in central retinal thickness (CRT) [ Time Frame: from month 0 to month 12 ]
  • the number of injections needed [ Time Frame: 12 months ]
  • the number of patients with improvement in BCVA from baseline [ Time Frame: 12 months ]
  • the number of patients with > 5, 10 and 15 letters improvement from baseline, the latter including patients reaching BCVA >84 [ Time Frame: 12 months ]
Same as current
Not Provided
Not Provided
 
Ranibizumab "Treat and Extend" in Diabetic Macular Edma
An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema
This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Diabetic Macular Edema
Drug: Ranibizumab
Experimental: Ranibizumab
Intervention: Drug: Ranibizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
7
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Visual impairment due to focal or diffuse macular edema with center involvement
  • Diabetes type 1 or 2, HbA1c < 12.0%
  • CRT = or > 250 μm

Exclusion Criteria:

  • Active inflammation or infection
  • Uncontrolled glaucoma
  • Iris neovascularization, active proliferative retinopathy or vitreomacular traction
  • Prior laser photocoagulation according to defined timelines
  • History of stroke, uncontrolled hypertension

Other protocol-defined inclusion/exclusion criteria may apply

Sexes Eligible for Study: All
18 Years to 18 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
 
NCT01297569
CRFB002DNO02
2010-021182-76 ( EudraCT Number )
Not Provided
Not Provided
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP